[Bone loss in men under androgen-deprivation therapy for prostate cancer].
Bone is a major target tissue for sex hormones and hypogonadism is a known cause of male osteoporosis. Androgen-deprivation therapy (ADT) for prostate cancer yields hypogonadotropic status and accelerates age-related decrease in bone mineral density. The risk for osteoporotic fractures is also increased which may lead to a shorter life expectancy for prostatic cancer patients. Baseline and follow up bone density measurement is desired for all men beginning ADT and it is advisable to take calcium and vitamin D as well as maintain a moderate exercise. Bisphosphonate is a possible treatment for those in whom osteoporosis develops. More data are desirable to make a guideline to prevent and treat male osteoporosis under ADT.
Ishizaka
Kazuhiro
K
Department of Urology, Kanto Central Hospital.
Machida
Tatsuya
T
Yoshida
Ken-Ichiro
K
D000726:Androgen Antagonists / Q000009:adverse effects*; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced* / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D000726:Androgen Antagonists